Psychedelic-Assisted Therapy for Major Depressive Disorder (MDD)

** MARCH 2022 – TRIAL CLOSED. No longer accepting candidates for this study.**

If you are between the ages of 21 and 65, you may be eligible for a clinical trial examining psilocybin-assisted therapy and depression. Dr. Keith Heinzerling and researchers at the Treatment & Research In Psychedelics (TRIP) Program at Pacific Neuroscience Institute want to find out if a drug called psilocybin can be safe and effective for treating Major Depressive Disorder (MDD). Psilocybin is an investigational drug. This means that the US Food and Drug Administration (FDA) has not approved psilocybin for the treatment of MDD, and psilocybin can only be given in a research study. Sponsor: USONA